PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements In Chloride Channel Function In Cystic Fibrosis Patients PTC Therapeutics, Inc. (PTC) announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle SermetGaudelus, M.D., Ph.D.
Source: www.medicalnewstoday.comMinster Pharmaceuticals Plc Announces Positive Results From Phase II Trial Of Migraine With Aura Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo.
Source: www.medicalnewstoday.comGenOdyssee Receives Broad Product Applications Protection In EU For Founding Natural Evolution Technology GenOdyssee (GO), a biotechnology company dedicated to the discovery and development of improved 'next generation' human protein therapeutics, announced that it has received notice of allowance from the European Patent Office of its Patent Application no.3 785 733.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
